bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
090-10-1151

Order Name:
Apixaban Level (Eliquis)

 
Useful For:
Measuring apixaban concentration in selected clinical situations (eg, renal insufficiency, assessment of compliance, periprocedural measurement of drug concentration, suspected overdose, advanced age and extremes of body weight).
 
Methodology:
Chromogenic Assay
 
AliasesName:
Eliquis
 
 
 
Test Code:
090-10-1151

Order Name:
Apixaban Level (Eliquis)

 
Collection Specimen Or Container:
Blood/ Sodium citrate tube (Sodium Citrate 3.2% anticoagulant, Blue top) 3 mL, 1 tube
 
Specimen Testing Type:
Citrate plasma, minimum volume 0.5 mL
 
Sub Mission Container:
Plastic tube
 
Rejection Criteria:
Hemolysis: Hemoglobin > 300 mg/dL will be reject.
Lipemia: Triglyceride > 1,156 mg/dL will be reject.
Icterus: Bilirubin > 25 mg/dL will be reject.
Other:
     1.  Clotted specimen will be reject.
     2.  In patients receiving heparin for therapeutic purposes. Blood should not be drawn from a heparin catheter.
 
Specimen Stabillity:
Specimen Type Temperature Time
Platelet-poor plasma Room temperature, 18oC to 24oC 1 hour
Refrigerated, 2oC to 8oC 4 hours
 
 
 
Test Code:
090-10-1151

Order Name:
Apixaban Level (Eliquis)

 
Method detail:
Chromogenic Assay
 
Schedule:
Tested daily (24 hours)
 
Turnaround Time:
Collected specimen to report within 2 hours
 
Performing Location:
Hematology, Laboratory Department, Tel. 17254
 
Specimen Retention Time:
14 days
 
 
 
Test Code:
090-10-1151

Order Name:
Apixaban Level (Eliquis)

 
 
Clinical Information:
Apixaban, an oral anticoagulant that directly inhibits factor Xa, has been approved by the FDA for prophylaxis of thrombosis in atrial fibrillation and surgical patients and treatment of venous thromboembolism (VTE). Unlike warfarin, it does not require routine therapeutic monitoring. However, in selected clinical situations, measurement of drug level would be useful (eg, renal insufficiency, assessment of compliance, periprocedural measurement of drug concentration, suspected overdose, advanced age, and extremes of body weight).
 
Reference Value:
1.  For stroke prevention in nonvalvular atrial fibrillation
     -  Peak concentration: 91-321 ng/mL
     -  Trough concentration: 41-230 ng/mL

2.  For treatment PE/VTE
     -  Peak concentration : 59-302 ng/mL
     -  Trough concentration : 22-177 ng/mL
 
Interpretation:
See Clinical Information for peak and trough drug concentrations observed in clinical trials of Apixaban.
 
Clinical Reference:
  1. Manufacturer’s reagent package insert, Liquid Anti-Xa, HemosIL®, Instrumentation Laboratory Company - Bedford, MA 01730-2443 (USA), Instrumentation Laboratory SpA - V.le Monza 338 - 20128 Milano (Italy), 06/2017
  2. https://www.mayocliniclabs.com (Retrieved: 15 Nov 2020)